Bristol Myers Squibb (CELG-RI) Shareholder's Equity Growth (3y) (2012 - 2026)

Bristol Myers Squibb (CELG-RI) Shareholder's Equity Growth (3y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Bristol Myers Squibb - - 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 309.61%
Dec 31, 2025 154.17%
Sep 30, 2025 188.92%
Jun 30, 2025 26.02%
Mar 31, 2025 65.00%
Dec 31, 2024 -14.45%
Sep 30, 2024 -81.25%
Jun 30, 2024 0.00%
Mar 31, 2024 -44.17%
Dec 31, 2023 5.62%
Sep 30, 2023 -17.49%
Jun 30, 2023 -41.07%
Mar 31, 2023 -81.99%
Dec 31, 2022 -26.60%
Sep 30, 2022 -26.98%
Jun 30, 2022 -61.15%
Mar 31, 2022 -83.81%
Dec 31, 2021 528.38%
Sep 30, 2021 47.69%
Jun 30, 2021 -71.35%